On the stock market since 2021, it operates in the world of health and science. It has 109 employees. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 28% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The growth engine is running at low revs right now. Report-card grade: 22/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 36/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 37/100.
On our five-subject report card, CGEM sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CGEM is a high-risk stock — not yet profitable, and its future rides on its product catching on.